About TRIA-662^TM

TRIA-662^TM is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal fat levels in the bloodstream. In preliminary human studies, TRIA-662^TM demonstrated the potential to provide the desirable benefits of niacin therapy without flushing. Niacin was the first lipid-modifying agent proven in outcomes trials to extend life, yet the side-effects of niacin, principally skin flushing, cause many patients to discontinue therapy and dramatically limit the drug’s potential. Previous efforts to create a flush-free niacin therapeutic – using extended release formulations, dose titration and, more recently, fixed dose combination technologies – have not been successful. As a result, TRIA-662^TM represents an important opportunity as a new first-line therapy in the multi-billion dollar cardiovascular risk reduction market.